Hemofiltration_NP ,_, adsorption_NN ,_, sieving_VBG and_CC the_DT challenge_NN of_IN sepsis_NN therapy_NN design_NN Abstract_NP |_SYM Circulating_VBG inflammatory_JJ mediators_NNS spilling_VBG into_IN the_DT circulation_NN from_IN sites_NNS of_IN active_JJ inflammation_NN are_VBP considered_VBN the_DT source_NN of_IN remote_JJ tissue_NN injury_NN and_CC associated_JJ organ_NN dysfunction_NN in_IN sepsis_NN ._SENT Hemofiltration_NP has_VBZ been_VBN proposed_VBN as_IN a_DT therapy_NN for_IN sepsis_NN based_VBN on_IN its_PP$ ability_NN to_TO remove_VB circulating_VBG inflammatory_JJ mediators_NNS by_IN sieving_VBG or_CC by_IN adsorption_NN ,_, or_CC both_DT ._SENT Designing_VBG devices_NNS and_CC methods_NNS for_IN sepsis_NN therapy_NN will_MD require_VB optimization_NN of_IN these_DT two_CD mechanisms_NNS ._SENT In_IN the_DT present_JJ issue_NN of_IN Critical_NP Care_NP Forum_NP ,_, Kellum_NP and_CC Dishart_NP report_VBP the_DT relative_JJ effects_NNS of_IN sieving_VBG and_CC adsorption_NN on_IN plasma_NN IL-6_NN following_VBG cecal_JJ ligation_NN and_CC puncture_NN in_IN rats_NNS ._SENT The_DT authors_NNS conclude_VBP that_IN hemoadsorption_NN is_VBZ the_DT main_JJ mechanism_NN of_IN removal_NN ,_, and_CC discuss_VB some_DT possible_JJ implications_NNS for_IN filter_NN design_NN but_CC hemoadsorption_NN is_VBZ well_RB dependant_JJ on_IN hemofiltration_NN (_( the_DT so-called_JJ hemofiltration_NN filter_NN adsorption/synergistic_JJ effect_NN )_) ._SENT It_PP is_VBZ important_JJ to_TO recognize_VB the_DT limitations_NNS of_IN conventional_JJ systems_NNS ;_: Kellum_NP and_CC Dishart_NP have_VBP extended_VBN our_PP$ knowledge_NN of_IN hemofiltration_NN filter_NN adsorption_NN ,_, which_WDT is_VBZ quite_RB different_JJ from_IN conventional_JJ hemoadsorption_NN ._SENT If_IN sepsis_NN is_VBZ a_DT manifestation_NN of_IN a_DT nonlinear_JJ dynamic_JJ control_NN system_NN out_IN of_IN control_NN ,_, then_RB filtration_NN at_IN modest_JJ doses_NNS with_IN a_DT large_JJ pore_NN filter_NN may_MD succeed_VB as_RB well_RB as_IN high-volume_JJ hemofiltration_NN with_IN a_DT conventional_JJ cut-off_NN filter_NN ._SENT In_IN the_DT present_JJ paper_NN ,_, we_PP will_MD explore_VB the_DT strengths_NNS and_CC the_DT weaknesses_NNS of_IN the_NP '_POS Kellum_NP and_CC Dishart_NP '_POS study_NN and_CC discussing_VBG their_PP$ findings_NNS in_IN the_DT light_NN of_IN the_DT current_JJ available_JJ literature_NN ._SENT adsorption_NN ,_, hemofiltration_NN ,_, membrane_NN ,_, sepsis_NN ,_, sieving_VBG ,_, Circulating_VBG inflammatory_JJ mediators_NNS (_( IM_NN )_) spilling_VBG into_IN the_DT circulation_NN from_IN sites_NNS of_IN active_JJ inflammation_NN are_VBP considered_VBN the_DT source_NN of_IN remote_JJ tissue_NN injury_NN and_CC associated_JJ organ_NN dysfunction_NN in_IN sepsis_NN ._SENT Hemofiltration_NP has_VBZ been_VBN proposed_VBN as_IN a_DT therapy_NN for_IN sepsis_NN based_VBN on_IN its_PP$ ability_NN to_TO remove_VB circulating_VBG IM_NNS by_IN sieving_VBG or_CC by_IN adsorption_NN ,_, or_CC both_DT ._SENT Designing_VBG devices_NNS and_CC methods_NNS for_IN sepsis_NN therapy_NN will_MD require_VB optimization_NN of_IN these_DT two_CD mechanisms_NNS ._SENT In_IN the_DT present_JJ issue_NN of_IN Critical_NP Care_NP Forum_NP ,_, Kellum_NP and_CC Dishart_NP report_VBP the_DT relative_JJ effects_NNS of_IN sieving_VBG and_CC adsorption_NN on_IN plasma_NN IL-6_NN following_VBG cecal_JJ ligation_NN and_CC puncture_NN in_IN rats_NNS ._SENT The_DT authorsconclude_NN that_IN hemoadsorption_NN is_VBZ the_DT main_JJ mechanism_NN of_IN removal_NN ,_, and_CC discuss_VB some_DT possible_JJ implications_NNS for_IN filter_NN design_NN ._SENT Hemoadsorption_NP is_VBZ dependent_JJ on_IN membrane_NN material_NN and_CC filtration_NN operating_VBG parameters_NNS (_( e.g._FW filtration_NN fraction_NN :_: the_DT so-called_JJ adsorption/synergistic_JJ effect_NN )_) ._SENT If_IN hemofiltration_NN is_VBZ to_TO be_VB an_DT effective_JJ therapy_NN in_IN the_DT complexity_NN of_IN sepsis_NN ,_, then_RB proper_JJ design_NN of_IN its_PP$ material_NN and_CC operational_JJ characteristics_NNS must_MD be_VB pursued_VBN ._SENT Adsorption_NN of_IN proteins_NNS to_TO membrane_NN materials_NNS is_VBZ well_RB recognized_VBN in_IN pharmaceutical_JJ manufacturing_NN ,_, food_NN processing_NN and_CC medical_JJ filtration_NN ._SENT The_DT type_NN and_CC extent_NN of_IN feed_NN solution_NN proteins_NNS adsorbed_VBN depends_VBZ on_IN the_DT membrane_NN material_NN ,_, the_DT pH_NN ,_, ionic_JJ strength_NN and_CC composition_NN of_IN the_DT feed_NN solution_NN ,_, the_DT pore_NN size_NN ,_, the_DT membrane_NN morphology_NN and_CC the_DT presence_NN of_IN a_DT polarization_NN layer_NN ._SENT Membrane_NN materials_NNS vary_VBP in_IN the_DT extent_NN and_CC type_NN of_IN cytokines_NNS adsorbed_VBD ._SENT Data_NNS from_IN in_IN vitro_NN studies_NNS reveal_VBP tumor_NN necrosis_NN factor_NN adsorption_NN of_IN 30_CD --_: 32_CD %_NN for_IN polyamide_NN and_CC AN69_NP ,_, and_CC of_IN 0_CD %_NN for_IN cellulose_NN acetate_NN and_CC polysulfone_NN ._SENT IL-1_JJ adsorption_NN was_VBD 40_CD %_NN for_IN polyacrylonitrile_NN ,_, 0_CD --_: 11_CD %_NN for_IN polysulfone_NN ,_, 2_CD %_NN for_IN AN69_NP and_CC 0_CD %_NN for_IN polyamide_NN ._SENT Birk_NP et_FW al._FW found_VBD an_DT approximately_RB sixfold_JJ difference_NN in_IN total_JJ plasma_NN protein_NN adsorption_NN between_IN different_JJ membrane_NN materials_NNS ._SENT Total_JJ protein_NN adsorption_NN was_VBD negatively_RB correlated_VBN with_IN the_DT adsorption_NN of_IN proteins_NNS with_IN molecular_JJ weight_NN <65_NN kDa_NN ._SENT The_DT feed_NN solution_NN pH_NN and_CC ionic_JJ strength_NN significantly_RB affect_VB adsorption_NN and_CC polarization_NN ,_, as_RB shown_VBN in_IN vitro_NN ._SENT At_IN pH4.8_NN ,_, the_DT sieving_VBG coefficient_NN (_( SC_NP )_) for_IN albumin_NN and_CC the_DT SC_NP for_IN IgG_NP are_VBP ~0.45_JJ and_CC 0_CD ,_, respectively_RB ._SENT At_IN pH7.4_NN ,_, however_RB ,_, these_DT SCs_NP are_VBP 0.38_CD and_CC 0.85_CD ,_, a_DT substantial_JJ reversal_NN ._SENT At_IN equal_JJ concentration_NN ,_, mixtures_NNS of_IN IgG_NP and_CC albumin_NN reduce_VBP filtrate_NN flux_NN and_CC protein_NN diffusivity_NN more_JJR than_IN pure_JJ solutions_NNS ;_: this_DT results_NNS from_IN protein_NN --_: protein_NN interactions_NNS ._SENT Generally_RB ,_, these_DT factors_NNS cannot_MD be_VB manipulated_VBN in_IN clinical_JJ hemofiltration_NN ._SENT Membranes_NNS with_IN a_DT higher_JJR molecular_JJ weight_NN cut-off_NN (_( MWCO_NP )_) adsorb_VBP more_JJR protein_NN than_IN lower_JJR MWCO_NP membranes_NNS ._SENT Uptake_NN of_IN radiolabeled_JJ albumin_NN by_IN a_DT 100_CD kDa_NP MWCO_NP polysulfone_NN membrane_NN was_VBD nearly_RB double_JJ that_IN of_IN a_DT 30_CD kDa_NP MWCO_NP membrane_NN ._SENT Protein_NN uptake_NN occurred_VBD preferentially_RB in_IN larger_JJR pores_NNS ._SENT This_DT pattern_NN of_IN protein_NN uptake_NN has_VBZ significant_JJ implications_NNS for_IN molecular_JJ sieving_VBG ._SENT Molecular_JJ sieving_VBG in_IN AN69_NP membranes_NNS was_VBD characterized_VBN using_VBG polydisperse_JJ dextran_NN before_IN and_CC after_IN blood_NN contact_NN ._SENT The_DT SC_NP for_IN dextran_NN of_IN molecular_JJ weight_NN <5_NN kDa_NN was_VBD reduced_VBN by_IN 14_CD %_NN ,_, and_CC the_DT SC_NP for_IN 20_CD kDa_NN dextran_NN was_VBD reduced_VBN by_IN 60_CD %_NN ._SENT Protein_NN (_( including_VBG cytokine_NN )_) adsorption_NN and_CC polarization_NN of_IN filtration_NN membranes_NNS have_VBP been_VBN extensively_RB studied_VBN ._SENT Awareness_NN of_IN these_DT characteristics_NNS is_VBZ essential_JJ in_IN designing_VBG filtration_NN therapy_NN for_IN sepsis_NN ._SENT Some_DT design_NN elements_NNS relevant_JJ to_TO adsorption_NN are_VBP fixed_VBN for_IN a_DT given_VBN system_NN (_( e.g._FW membrane_NN materials_NNS ,_, morphology_NN and_CC surface_NN area_NN )_) ,_, and_CC some_DT do_VBP not_RB permit_VB manipulation_NN (_( e.g._FW patient_JJ plasma_NN protein_NN composition_NN ,_, pH_NN and_CC ionic_JJ strength_NN )_) ._SENT However_RB ,_, as_IN membrane_NN adsorption_NN is_VBZ rapidly_RB saturated_JJ (_( 30_CD to_TO 50_CD minutes_NNS )_) ._SENT Recent_JJ recognition_NN that_IN the_DT intensity_NN of_IN ultrafiltration_NN needs_VBZ to_TO be_VB adjusted_VBN for_IN patient_JJ body_NN size_NN and_CC severity_NN of_IN illness_NN supports_VBZ the_DT need_NN to_TO focus_VB on_IN sieving_VBG and_CC filtrate_NN flow_NN as_IN promising_JJ points_NNS for_IN new_JJ designs_NNS ._SENT The_DT design_NN of_IN blood_NN filtration_NN in_IN sepsis_NN should_MD focus_VB on_IN those_DT characteristics_NNS of_IN hemofiltration_NN that_WDT permit_VBP greater_JJR effectiveness_NN in_IN controlling_VBG sepsis_NN and_CC that_WDT provide_VBP operational_JJ flexibility_NN so_IN the_DT therapy_NN may_MD be_VB tuned_VBN to_TO patient_JJ body_NN size_NN and_CC severity_NN of_IN illness_NN ._SENT This_DT process_NN begins_VBZ with_IN recognition_NN of_IN key_JJ features_NNS of_IN the_DT inflammatory_JJ response_NN ._SENT The_DT network_NN of_IN IM_NN ,_, acting_VBG as_IN a_DT nonlinear_JJ dynamic_JJ control_NN system_NN ,_, drives_VBZ the_DT inflammatory_JJ response_NN ._SENT Network_NN effects_NNS make_VBP the_DT inflammatory_JJ response_NN robust_JJ against_IN large_JJ narrowly_RB focused_VBN changes_NNS ;_: this_DT robustness_NN probably_RB explains_VBZ the_DT failure_NN of_IN drugs_NNS directed_VBN against_IN some_DT single_JJ IM_NN ._SENT Control_NN networks_NNS may_MD be_VB manipulated_VBN by_IN application_NN of_IN small_JJ changes_NNS in_IN the_DT activity_NN to_TO many_JJ network_NN elements_NNS ._SENT The_DT more_JJR elements_NNS (_( e.g._FW IM_NN )_) affected_VBN ,_, the_DT smaller_JJR the_DT change_NN in_IN their_PP$ aggregate_JJ activity_NN required_VBN for_IN system_NN control_NN ._SENT Applied_VBN to_TO blood_NN filtration_NN in_IN sepsis_NN ,_, either_CC high_JJ doses_NNS of_IN filtration_NN with_IN a_DT conventional_JJ filter_NN ,_, or_CC lower_JJR doses_NNS with_IN a_DT large_JJ pore_NN filter_NN should_MD be_VB effective_JJ ._SENT In_IN their_PP$ study_NN ,_, Kellum_NP and_CC Dishart_NP used_VBD an_DT appropriate_JJ animal_NN model_NN (_( ceacal_JJ ligation_NN and_CC puncture_NN )_) relevant_JJ in_IN its_PP$ initial_JJ insult_NN and_CC delay_NN in_IN treatment_NN ._SENT According_VBG to_TO the_DT average_JJ body_NN weight_NN for_IN adult_NN ,_, male_JJ Sprague-Dawley_NP rats_NNS reported_VBD (_( 486_CD g_NN )_) and_CC to_TO the_DT ultrafiltration_NN flow_NN rate(Quf)_NN reported_VBN (_( 30_CD ml/hour_NN )_) ,_, we_PP can_MD conclude_VB that_IN a_DT dose_NN of_IN ~62_JJ ml/kg_NN (_( which_WDT for_IN a_DT 75_CD kg_NNS human_JJ being_VBG represent_VB 4.5_CD l/kg_NN per_IN hour_NN )_) was_VBD delivered_VBN ._SENT This_DT dose_NN is_VBZ greater_JJR than_IN the_DT highest_JJS dose_NN used_VBN by_IN Ronco_NP et_FW al._FW (_( 45_CD ml/kg_NN per_IN hour_NN )_) and_CC clinically_RB relevant_JJ as_IN high-volume_JJ hemofiltration_NN is_VBZ usually_RB defined_VBN to_TO be_VB greater_JJR than_IN 50_CD ml/kg_NN per_IN hour_NN ._SENT However_RB when_WRB looking_VBG at_IN literature_NN ,_, usual_JJ average_JJ body_NN weight_NN for_IN adult_NN ,_, male_JJ Sprague-Dawley_NP rats_NNS is_VBZ about_RB 580_CD g_NN ._SENT In_IN the_DT study_NN of_IN Kellum_NP and_CC Dishart_NP ,_, Quf_NP was_VBD not_RB controlled_VBN or_CC indexed_VBN to_TO body_NN weight_NN ._SENT Recent_JJ demonstrations_NNS of_IN dose-response_NN effects_NNS of_IN hemofiltration_NN in_IN human_JJ acute_JJ renal_JJ failure_NN and_CC sepsis_NN make_VBP indexing_VBG Quf_NP to_TO body_VB weight_NN a_DT critical_JJ parameter_NN to_TO assess_VB or_CC control_VB ._SENT Filter_NP blood_NN flow_NN was_VBD spontaneous_JJ and_CC not_RB quantified_VBN ;_: however_RB the_DT high_JJ Quf_NP suggest_VBP an_DT high_JJ filtration_NN fraction_NN prevailed_VBD ._SENT Low_JJ filtration_NN fraction_NN promotes_VBZ IM_JJ sieving_VBG ,_, high_JJ filtration_NN fraction_NN promotes_VBZ adsorption_NN and_CC reduces_VBZ sieving_VBG of_IN IM_NN ._SENT What_WP evidences_VBZ support_VB effective_JJ sieving_VBG of_IN IM_NN in_IN sepsis_NN ?_SENT Honore_NP et_FW al._FW replaced_VBD 35_CD l_NN of_IN ultrafiltratein_NN 4_CD hours_NNS (_( using_VBG high-volume_JJ hemofiltration_NN )_) in_IN 20_CD patients_NNS with_IN refractory_JJ septic_JJ shock_NN using_VBG a_DT polysulfone_NN membrane_NN (_( Fresenius_NP ,_, MWCO_NP =_SYM 35_CD kDa_NN )_) ._SENT Predicted_VBN mortality_NN for_IN the_DT group_NN was_VBD 79_CD %_NN ,_, and_CC observed_VBD mortality_NN was_VBD 55_CD %_NN (_( P_NN <_SYM 0.05_CD )_) ._SENT Patients_NNS who_WP responded_VBD (_( improved_VBN to_TO specified_VBN end_NN points_NNS )_) hemodynamically_RB by_IN the_DT end_NN of_IN the_DT 4_CD hours_NNS survived_VBD significantly_RB more_RBR often_RB (_( 9/11_CD )_) than_IN those_DT patients_NNS that_WDT did_VBD not_RB respond_VB (_( 0/9_CD survived_VBD 24_CD hours_NNS )_) ._SENT Retrospective_JJ analysis_NN of_IN the_DT study_NN of_IN Honore_NP et_FW al._FW revealed_VBD that_IN responders_NNS were_VBD smaller_JJR (_( 66.2_CD +-_NN 8.4_CD kg_NN )_) than_IN nonresponders_NNS (_( 82.6_CD +-_NN 13.4_CD kg_NN )_) and_CC therefore_RB received_VBD a_DT larger_JJR dose_NN of_IN filtration_NN (_( 0.53_CD +-_NN 0.07_CD l/kg_NN per_IN 4_CD hours_NNS [_SYM +-_JJ 150_CD ml/kg_NN per_IN hour_NN of_IN hemofiltration_NN clearance_NN indexed_VBN to_TO body_NN weight_NN and_CC time_NN ]_SYM and_CC 0.43_CD +-_NN 0.07_CD l/kg_NN per_IN 4_CD hours_NNS [_SYM +-_JJ 110_CD ml/kg_NN per_IN hour_NN of_IN hemofiltration_NN clearance_NN indexed_VBN to_TO body_NN weight_NN and_CC time_NN ]_SYM ,_, respectively_RB )_) ._SENT Retrospective_JJ analysis_NN of_IN the_DT study_NN of_IN Honore_NP et_FW al._FW suggests_VBZ that_IN a_DT sufficiently_RB high_JJ dose_NN allows_VBZ ~82_JJ %_NN improvement_NN in_IN survival_NN ._SENT The_DT same_JJ protocol_NN applied_VBN to_TO all_DT patients_NNS ,_, thus_RB adsorption_NN should_MD be_VB similar_JJ in_IN all_DT patients_NNS ;_: adsorption_NN should_MD be_VB saturated_VBN by_IN 30_CD to_TO 50_CD minutes_NNS ._SENT Thus_RB the_DT dominant_JJ mechanism_NN of_IN IM_JJ removal_NN should_MD be_VB sieving_VBG ._SENT Survival_NN was_VBD not_RB assess_VB in_IN the_DT study_NN of_IN Kellum_NP and_CC Dishart_NP ._SENT A_DT large_JJ pore_NN filter_NN (_( polysulfone_NP ,_, MWCO_NP =_SYM 100_CD kDa_NN )_) has_VBZ been_VBN used_VBN in_IN a_DT swine_NN model_NN of_IN lethal_JJ sepsis_NN ._SENT In_IN a_DT paired_VBN study_NN with_IN a_DT similar_JJ conventional_JJ filter_NN (_( MWCO_NP =_SYM 50_CD kDa_NN )_) ,_, and_CC using_VBG identical_JJ operating_VBG parameters_NNS (_( e.g._FW equal_JJ filtration_NN fraction_NN )_) the_DT 100_CD kDa_NN filter_NN was_VBD associated_VBN with_IN a_DT survival_NN time_NN nearly_RB twice_RB that_IN of_IN the_DT 50_CD kDa_NN filter_NN ._SENT A_DT similar_JJ filter_NN (_( polyamide_NN ,_, MWCO_NP =_SYM 100_CD kDa_NN )_) has_VBZ been_VBN studied_VBN in_IN vitro_NN by_IN Uchino_NP et_FW al._FW using_VBG recirculating_VBG human_JJ blood_NN ._SENT The_DT blood_NN was_VBD spiked_VBN with_IN endotoxin_NN to_TO raise_VB a_DT cytokine_NN response_NN ._SENT Selected_JJ results_NNS are_VBP compared_VBN in_IN Table_NP with_IN conventional_JJ filters_NNS ._SENT Table_NP 1_CD |_SYM Sieving_NP coefficients_NNS of_IN large_JJ pore_NN membranes_NNS and_CC conventional_JJ pore_NN membranes_NNS The_DT 100_CD kDa_NN membrane_NN has_VBZ two_CD significant_JJ advantages_NNS ._SENT First_RB ,_, for_IN IM_NNS sieved_VBN by_IN conventional_JJ and_CC the_DT 100_CD kDa_NN membrane_NN ,_, the_DT 100_CD kDa_NN exhibits_VBZ higher_JJR SC_NP ._SENT Second_RB ,_, the_DT 100_CD kDa_NN sieves_NNS cytokine_NN not_RB sieved_VBN by_IN conventional_JJ membrane_NN ._SENT If_IN sepsis_NN is_VBZ a_DT manifestation_NN of_IN a_DT nonlinear_JJ dynamic_JJ control_NN system_NN operating_VBG at_IN an_DT excessive_JJ and_CC injurious_JJ level_NN ,_, then_RB filtration_NN at_IN modest_JJ doses_NNS with_IN a_DT large_JJ pore_NN filter_NN may_MD succeed_VB ;_: high-volume_JJ hemofiltration_NN with_IN a_DT conventional_JJ MWCO_NP should_MD also_RB be_VB effective_JJ ._SENT A_DT successful_JJ blood_NN filtration_NN therapy_NN for_IN sepsis_NN and_CC septic_JJ shock_NN will_MD not_RB be_VB found_VBN by_IN accident_NN --_: it_PP will_MD be_VB designed_VBN ._SENT It_PP is_VBZ important_JJ to_TO recognize_VB the_DT limitations_NNS of_IN conventional_JJ systems_NNS ._SENT Kellum_NP and_CC Dishart_NP have_VBP shown_VBN that_IN hemofiltration_NN filter_NN adsorption_NN occurs_VBZ and_CC exhibits_VBZ meaningful_JJ biologic_JJ effects_NNS ._SENT The_DT design_NN of_IN successful_JJ blood_NN filtration_NN therapy_NN in_IN sepsis_NN will_MD require_VB recognition_NN of_IN the_DT limitations_NNS of_IN existing_VBG systems_NNS and_CC methods_NNS ._SENT The_DT Kellum_NP and_CC Dishart_NP study_NN aids_VBZ this_DT recognition_NN ._SENT Recognition_NN that_IN IM_NNS are_VBP not_RB operative_JJ as_IN single_JJ agents_NNS ,_, but_CC are_VBP closely_RB integrated_VBN in_IN a_DT self-regulated_JJ control_NN network_NN is_VBZ of_IN key_JJ importance_NN to_TO design_VB of_IN therapeutic_JJ systems_NNS ._SENT A_DT blood_NN filtration_NN system_NN which_WDT filters_VBZ a_DT sufficiently_RB wide_JJ of_IN IM_NN to_TO be_VB effective_JJ in_IN sepsis_NN ,_, and_CC has_VBZ the_DT operation_NN flexibility_NN to_TO readily_RB adapt_VB to_TO patients_NNS of_IN different_JJ body_NN size_NN and_CC severity_NN of_IN illness_NN will_MD require_VB careful_JJ design_NN ._SENT In_IN matters_NNS of_IN membrane_NN separation_NN and_CC system_NN control_NN ,_, our_PP$ engineering_NN colleagues_NNS have_VBP much_RB to_TO offer_VB ._SENT Partnering_VBG with_IN industry_NN and_CC engineering_NN should_MD allow_VB new_JJ devices_NNS and_CC methods_NNS to_TO be_VB developed_VBN and_CC tested_VBN ._SENT This_DT should_MD be_VB done_VBN before_IN we_PP embark_VBP upon_IN a_DT large_JJ scale_NN multicentre_NN study_NN ._SENT By_IN viewing_VBG the_DT whole_JJ problem_NN ,_, we_PP can_MD work_VB out_RP the_DT whole_JJ solution_NN ._SENT None_NN declared_VBD ._SENT IL_NN =_SYM interleukin_NN ;_: IM_NNS =_SYM inflammatory_JJ mediators_NNS ;_: MWCO_NP =_SYM molecular_JJ weight_NN cut-off_NN ;_: SC_NP =_SYM sieving_VBG coefficient_NN ._SENT 